Breaking News: Myriad Genetics Acquires Gateway Genomics | Learn More
Knowing your patient’s hereditary cancer risk is critical when it comes to making treatment decisions. Blending both genetic test status and personal cancer family history, the MyRisk Hereditary Cancer Panel represents the next generation of hereditary cancer risk testing. MyRisk is here to help you determine the right treatment for your patients with a report including comprehensive results and a guideline-based Medical Management Tool.
3 out of 4 patients pay $0
Average turnaround time is 7-14 days
We make genetic testing simple for your patients and your practice
Commitment to providing broad patient access
MyRisk Hereditary Cancer Panel
Multi-gene panel determines hereditary cancer risk associated with 11 cancer sites:
MyRisk Management Tool (MMT)
The MyRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the MyRisk Genetic Result and a personalized MyRisk Medical Management Tool based on professional society guidelines.
With Myriad Complete, we support you and your patients throughout the genetic screening process:
These solutions allow for seamless integration of Myriad Genetics’ prenatal screens into your clinical care routines to help patients better understand and benefit from their results.
Patients and providers are at the center of our mission to make genetic testing and data-driven medical information more widely available. Beginning in Spring 2023, we will be sharing clinically impactful hereditary cancer and prenatal data submissions with the ClinVar public database. We will continue to identify ways to leverage our datasets as we work to advance health and well-being for all, and enable healthcare providers to better detect, treat, and prevent disease.
Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years
Invested in research over the past 5 years
Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.
2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.